View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 26, 2022

Nanoscope doses first subject in Phase II Stargardt disease trial

The Phase II study will assess safety and efficacy of a single intravitreal injection of MCO-010 in Stargardt disease patients.

This image has an empty alt attribute; its file name is Cytiva-CTA-1024x101.png

Nanoscope Therapeutics has dosed the first participant in a Phase II trial of its MCO-010 clinical stage gene therapy to treat Stargardt disease.

The Phase II STARLIGHT open-label trial has been designed to evaluate safety and efficacy of a single intravitreal injection of MCO-010 Optogenetic Therapy in Stargardt disease patients.

The MCO-010 gene therapy reprogrammes healthy retinal cells for making them photosensitive.

Using proprietary vector and promoter technology, the therapy delivers the Multi-Characteristic Opsins (MCO) genes into retinal bipolar cells to enable the vision in different colour environments.

It has received orphan drug designations from the US Food and Drug Administration (FDA) for Retinitis Pigmentosa (RP) and Stargardt diseases.

About six participants will be enrolled in the Phase II trial, which currently has active clinical sites in Texas and Florida, US.

In the trial, the participants will receive the same MCO-010 dose of 1.2E11gc/eye which was also used in the Phase IIb RP study.

The data from the six-month study is expected in the first quarter of next year.

Nanoscope Therapeutics advisor Stephen Tsang said: “MCO-010 offers new hope for individuals with Stargardt macular degeneration.

“Stargardt patients with severe degeneration typically lack sufficient light sensing photoreceptor neurons needed to qualify for experimental ABCA4 gene specific therapies.

“Optogenetic therapy may be able to treat a wider group of patients with Juvenile macular degeneration regardless of the status of their light sensing photoreceptor neurons.”

At present, the company’s gene therapy is also being evaluated in double-masked, multicentre, sham-controlled, randomised Phase IIb clinical trials in the US to treat RP.

Top line data from the study is expected in the first quarter of next year.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Related Companies
Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena